A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Key Who May Qualify: - Males or non-pregnant females aged between 18 and 75 years (inclusive) at time of signing the willing to sign a consent form form (ICF). - Participants must have type 2 diabetes mellitus diagnosed at least 3 months before screening or at least 2 metabolic risk factors. - Biopsy-confirmed fibrosis stage F4 MASH (NASH Clinical Research Network (CRN) system) with compensated cirrhosis. - Body mass index (BMI) at screening ≥25.0 (≥23.0 for Asian participants) and \<50.0 kilograms (kg)/meters squared (m\^2). Key Who Should NOT Join This Trial: - Liver disorder other than MASH. - History or evidence of hepatic decompensation. - History or evidence of hepatocellular carcinoma. - Have type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus. - ALT or aspartate aminotransferase (AST) ≥250 units per liter (U/L). - Participants taking vitamin E (\>400 international units \[IU\]/day) must be on stable dose for at least 6 months prior to screening. Other protocol-defined inclusion and exclusion criteria may apply. Always talk to your doctor about whether this trial is right for you.